Many techniques are currently required to characterize the full range of genomic variation that can cause or contribute to the initiation and progression of cancer.
While next-generation sequencing is becoming increasingly routine in cancer research laboratories, it fails to address a number of key genomic drivers or markers of cancer, such as structural variations, DNA methylation and transcript isoforms.
Download this whitepaper to discover how nanopore sequencing provides:
- Unrestricted read length
- Enhanced targeted sequencing capabilities
- Rapid, real-time results
- Cost-effective, scalable and on-demand analysis
